Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Male, but not female, SART1(+/-) mice showed significant up-regulation of HIF-1α in circulating and liver-infiltrating immune cells, but not in hepatocytes, before development of malignancy.
|
26799785 |
2016 |
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Male, but not female, SART1(+/-) mice showed significant up-regulation of HIF-1α in circulating and liver-infiltrating immune cells, but not in hepatocytes, before development of malignancy.
|
26799785 |
2016 |
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The results indicate that hypoxia leads to the elevation of HAF plus activation of the NF-κB pathway, accompanied by the switch of HIF-1α to HIF-2α, resulting in the enhanced ability of malignancy in T24 cells.
|
24316875 |
2014 |
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
These findings demonstrate a prominent role for the spliceosome in mediating Mcl1 activity and suggest that drugs that target either the specific UBL5/PRPF8/SART1 subcomplex or SF3b functions may have a role as cancer therapeutics by attenuating the Mcl1 survival bias present in numerous cancers.
|
24556687 |
2014 |
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
These findings demonstrate a prominent role for the spliceosome in mediating Mcl1 activity and suggest that drugs that target either the specific UBL5/PRPF8/SART1 subcomplex or SF3b functions may have a role as cancer therapeutics by attenuating the Mcl1 survival bias present in numerous cancers.
|
24556687 |
2014 |
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The results indicate that hypoxia leads to the elevation of HAF plus activation of the NF-κB pathway, accompanied by the switch of HIF-1α to HIF-2α, resulting in the enhanced ability of malignancy in T24 cells.
|
24316875 |
2014 |
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
HAF, thus, switches the hypoxic response of the cancer cell from HIF-1α-dependent to HIF-2α-dependent transcription and activates genes involved in invasion such as MMP9, PAI-1, and the stem cell factor OCT-3/4.
|
21512133 |
2011 |
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
HAF, thus, switches the hypoxic response of the cancer cell from HIF-1α-dependent to HIF-2α-dependent transcription and activates genes involved in invasion such as MMP9, PAI-1, and the stem cell factor OCT-3/4.
|
21512133 |
2011 |
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
These results show that SART-1 gene transduction induces cell cycle arrest leading to apoptosis and suggest the possibility of gene therapy against cancer.
|
16158934 |
2005 |
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
These results show that SART-1 gene transduction induces cell cycle arrest leading to apoptosis and suggest the possibility of gene therapy against cancer.
|
16158934 |
2005 |
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Moreover, while HIF-1α, HIF-2α and HAF expression was heterogenous within tumors, we observed and confirmed that HIF-2α co-localized with HAF.
|
29481555 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma.
|
28572533 |
2017 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our data indicate that mutant VHL can protect HIF1α from SART1-dependent degradation in normoxic conditions, but this protection is lost in hypoxic settings, favoring hypoxia-dependent ccRCC proliferation.
|
25915846 |
2016 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Taken together, our results show that HAF is a specific mediator of HIF2 activation that is critical for CRCC development and morbidity.
|
25421578 |
2015 |
Malignant neoplasm of breast
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Particularly, the breast cancer associated allele of rs660118 SNP in the gene SART1 showed a near doubled frequency in glioblastoma patients, as verified in an independent control cohort by Sanger sequencing.
|
21695249 |
2011 |
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The switch to HIF-2α-dependent gene expression caused by HAF also promotes an enriched tumor stem cell population, resulting in highly aggressive tumors in vivo.
|
21512133 |
2011 |
Breast Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Particularly, the breast cancer associated allele of rs660118 SNP in the gene SART1 showed a near doubled frequency in glioblastoma patients, as verified in an independent control cohort by Sanger sequencing.
|
21695249 |
2011 |
Malignant neoplasm of breast
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The observed associations between breast cancer risk and genetic variation in the SART1 and EIF3A genes that are required for maintenance of normal mitosis suggest a direct role for these genes in the development of breast cancer.
|
19377877 |
2010 |
Breast Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The observed associations between breast cancer risk and genetic variation in the SART1 and EIF3A genes that are required for maintenance of normal mitosis suggest a direct role for these genes in the development of breast cancer.
|
19377877 |
2010 |
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
The SART-1(800)+ breast cancer cells transfected with HLA-A2601 or HLA-A2402 cDNA were recognized by the HLA-A26-restricted and SART-1-specific cytotoxic T lymphocytes (CTLs) or the HLA-A24-restricted and SART-1-specific CTLs, respectively.
|
9935232 |
1999 |
Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Among the 20 SART-1(800)+ tumors, 9 or 8 tumors expressed estrogen receptor or progesterone receptor, respectively.
|
9935232 |
1999 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The SART-1(800)+ breast cancer cells transfected with HLA-A2601 or HLA-A2402 cDNA were recognized by the HLA-A26-restricted and SART-1-specific cytotoxic T lymphocytes (CTLs) or the HLA-A24-restricted and SART-1-specific CTLs, respectively.
|
9935232 |
1999 |
Malignant neoplasm of kidney
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Patients with ccRCC with high HAF transcript or protein levels showed significantly decreased overall survival compared with those with low HAF.
|
30705246 |
2019 |
Renal carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Patients with ccRCC with high HAF transcript or protein levels showed significantly decreased overall survival compared with those with low HAF.
|
30705246 |
2019 |